期刊文献+

人BRCA1干涉慢病毒载体的构建与验证

Construction and Verification of Lentiviral Vectors Targeting for Human BRCA1 Gene
原文传递
导出
摘要 目的:设计合成干涉BRCA1表达的小干扰RNA,并克隆入pLKO.1慢病毒表达载体,为研究基因BRCA1在乳腺癌细胞增殖中的作用提供基础。方法:根据人BRCA1的基因序列,设计合成三对BRCA1干涉片段(序列前后加入酶切位点EcoRI和AgeI),再利用酶切连接反应将其插入到慢病毒载体pLKO.1中,经过酶切鉴定及测序正确后,将重组质粒转染入MCF-7细胞,48h后提取蛋白质和RNA,通过蛋白印迹验证BRCA1的蛋白水平的表达情况,Realtime PCR验证BRCA1的RNA水平的表达变化。结果:重组质粒经酶切鉴定和测序比对完全正确,转染乳腺癌细胞48h后可见BRCA1表达的明显下调。结论:成功构建BRCA1干涉的慢病毒载体,并且转染MCF-7细胞证实其能够下调BRCA1的表达,为后续研究BRCA1在乳腺癌细胞的功能奠定了基础。 Objective: To design and synthesize three small interference RNA targeting for human BRCA1 gene,and translate them into a lentiviral expression vector pLKO.1,lay the foundation for further study of BRCA1 functions in breast tumor cells.Methods: To construct the lentiviral vectors of small interference RNA targeting for BRCA1 gene.Three interference fragments were designed and synthesized based on human BRCA1 gene sequence,and then they were digested by double restriction enzymes and inserted into the lentiviral expression vector pLKO.1.After confirmation by enzyme digestion and sequencing,the constructed plasmids were transfected into MCF-7 breast tumor cells.48 hours later,BRCA1 expression were verified by Western-blot and real-time PCR.Results:Three small lentiviral plasmids were all 500 bp.The constructed recombination plasmids were verified by enzyme digestion and DNA sequencing.BRCA1 gene expression can be down-regulated in MCF-7 cells after transfection.Conclusion: The lentiviral vectors with siRNAs targeting human BRCA1 gene were successfully constructed,and they was able to down-regulate BRCA1 gene expression significantly in MCF-7 cells after cell transfection,which lays the foundation for the following studies.
出处 《现代生物医学进展》 CAS 2012年第17期3201-3204,共4页 Progress in Modern Biomedicine
基金 国家自然科学基金重点项目(30830054)
关键词 BRCA1 慢病毒载体 干涉 重组质粒 BRCA1 Lentiviral vector Interference Recombinant plasmid
  • 相关文献

参考文献22

  • 1Robinson-White, S. Patient navigation in breast cancer: a systematic review[J]. Cancer Nurs, 2010, 33(2): 127-140.
  • 2Rivera, P. and H. yon Euler. Molecular biological aspects on canine and human mammary tumors[J]. Vet Pathol, 2011,48(1): 132-146.
  • 3Spitzer, E. Detection of BRCAI and BRCA2 mutations in breast can- cer families by a comprehensive two-stage screening procedure[J]. Int J Cancer, 2000, 85(4): 474-481.
  • 4Miki, Y. A strong candidate for the breast and ovarian cancer suscepti- bility gene BRCA 1 [J]. Science, 1994, 266(5182): 66-71.
  • 5Arizti, P. Tumor suppressor p53 is required to modulate BRCAI ex- pression[J]. Mol Cell Biol, 2000, 20(20):7450-7459.
  • 6Srivastava, N. Role of H2AX in DNA damage response and human cancers[J]. Mutat Res, 2009, 681 (2-3): 180-188.
  • 7Altiok, S. Heregulin induces phosphorylation of BRCAI through phosphatidylinositol 3-Kinase/AKT in breast cancer cells [J], J Biol Chem, 1999,274(45): 32274-32278.
  • 8Baer, R. and T. Ludwig. The BRCA1/BARD1 heterodimer, a tumor suppressor complex with ubiquitin E3 ligase activity[J]. Curt Opin G- enet Dev, 2002, 12( I ):86-91.
  • 9BRCA1 (breast cancer type 1). Tumor suppressor gene[J]. Bull Cancer, 1998, 85(10): 833.
  • 10Antoniou, A.C. Parity and breast cancer risk among BRCA1 and BR- CA2 mutation carriers[J]. Breast Cancer Res, 2006,8(6):.R72.

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部